Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852543 | 0.87 | HDAC3 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5852664 | 0.84 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5852357 | 0.84 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6150548 | 0.81 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5853895 | 0.81 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5852604 | 0.80 | HDAC3 (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5854968 | 0.79 | HDAC3 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5852513 | 0.78 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5853937 | 0.76 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9757630 | 0.75 | KDM4E (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091229-B2 | Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | claimed |
| EP-1358168-B1 | TRICYCLIC LACTAM AND SULTAM DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | EP | claimed |
| US-20040077698-A1 | Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-04-22 | — | — | US | claimed |
| EP-1358168-A1 | TRICYCLIC LACTAM AND SULTAM DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | claimed |
| WO-2002062773-A1 | TRICYCLIC LACTAM AND SULTAM DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-15 | — | — | WO | claimed |
| US-7091229-B2 | Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1358168-B1 | TRICYCLIC LACTAM AND SULTAM DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20040077698-A1 | Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1358168-A1 | TRICYCLIC LACTAM AND SULTAM DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062773-A1 | TRICYCLIC LACTAM AND SULTAM DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077698-A1 | Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 9/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.